Research
Hormonal
Semaglutide 2.4 mg once weekly significantly reduces major adverse cardiovascular events (MACE) and all-cause mortality in individuals with obesity and established atherosclerotic cardiovascular disease (ASCVD), regardless of diabetes status.
If you have obesity and established heart disease, semaglutide 2.4 mg once weekly is a preferred first-line treatment to significantly reduce your risk of heart attacks, strokes, and death, even if you do not have diabetes. This should be combined with lifestyle therapy.
StrongSupportsVERY_HIGH confidence
In the SELECT trial, semaglutide 2.4 mg once weekly (OW) reduced MACE (CV death, nonfatal myocardial infarction (MI), stroke) by 20% (HR 0.80; 95% CI 0.72–0.90) and all-cause mortality by 19% in subjects with obesity and established ASCVD but without diabetes [4].
Why this rating
Based on a large, phase III randomized controlled trial (SELECT) with prespecified primary endpoints.
Source
Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan
Dario Tuccinardi et al. · Journal of Endocrinological Investigation · 2025
narrative_reviewCited 9×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →